Threatening auditory hallucinations and cotard syndrome in Parkinson disease

Clinical Neuropharmacology

Volumn 27, Issue 5, 2004, Pages 205-207

  Factor, Stewart A ^a   Molho, Eric S ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotics; Cotard syndrome; Parkinson disease; Psychosis; Schizophrenialike

Indexed keywords

AMANTADINE; ANXIOLYTIC AGENT; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LEVODOPA; PERGOLIDE; QUETIAPINE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; CLINICAL FEATURE; CONTROLLED DRUG RELEASE; COTARD SYNDROME; DELUSION; DEPRESSION; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; MENTAL DISEASE; MENTAL INSTABILITY; MINI MENTAL STATE EXAMINATION; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SLEEP DISORDER;

AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIBENZOTHIAZEPINES; FEMALE; HALLUCINATIONS; HUMANS; MIDDLE AGED; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS;

EID: 7444255514     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000144040.20600.c1     Document Type: Article

References (12)

1. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733-745.
2. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64:533-535.
3. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Edn 4. Washington, DC: American Psychiatric Association; 1994.
4. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001;70:734-738.
5. Pearn J, Gardner-Thorpe C. Jules Cotard (1840-1889): his life and the unique syndrome which bears his name. Neurology. 2002;58:1400-1403.
6. Jenkins RB, Groh RH. Mental symptoms in parkinsonian patients treated with L-dopa. Lancet. 1970;2:177-179.
7. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391-403.
8. Santhouse AM, Howard RJ, Ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain. 2000;123:2055-2064.
9. Kasai K, Iwanami A, Yamasue H, et al. Neuroanatomy and neurophysiology in schizophrenia. Neurosci Res. 2003;43:93-110.
10. Seidman LJ, Pantelis C, Keshavan MS, et al. A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull. 2003;29:803-830.
11. Hering R, Petrovic S, Mietz E-M, et al. Extended mutation analysis and association studies of Nurr 1 (NR4A2) in Parkinson's disease. Neurology. 2004;62:1231-1232.
12. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000;15:201-211.